{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T05:10:56Z","timestamp":1787893856610,"version":"build-2784847793"},"reference-count":51,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Perinatology"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.clp.2020.08.003","type":"journal-article","created":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T13:31:46Z","timestamp":1602855106000},"page":"733-742","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["An Update on Biologic Agents During Pregnancy"],"prefix":"10.1016","volume":"47","author":[{"given":"Ibrahim","family":"Hammad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. Flint","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.clp.2020.08.003_bib1","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1136\/ard.55.7.486","article-title":"Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases","volume":"55","author":"Buchanan","year":"1996","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"10.1016\/j.clp.2020.08.003_bib2","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1177\/0961203396005001141","article-title":"The use of hydroxychloroquine in lupus pregnancy: the British experience","volume":"5","author":"Khamashta","year":"1996","journal-title":"Lupus"},{"issue":"9305","key":"10.1016\/j.clp.2020.08.003_bib3","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S0140-6736(02)07643-2","article-title":"Antimalarial agents in pregnancy","volume":"359","author":"Motta","year":"2002","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.clp.2020.08.003_bib4","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1002\/art.11304","article-title":"Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group","volume":"48","author":"Costedoat-Chalumeau","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clp.2020.08.003_bib5","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1001\/archotol.1964.00750040419009","article-title":"The ototoxicity of chloroquine phosphate","volume":"80","author":"Hart","year":"1964","journal-title":"Arch Otolaryngol"},{"issue":"Suppl 92","key":"10.1016\/j.clp.2020.08.003_bib6","first-page":"1","article-title":"Ocular damage in chloroquine therapy","author":"Nylander","year":"1967","journal-title":"Acta Ophthalmol"},{"issue":"6","key":"10.1016\/j.clp.2020.08.003_bib7","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1191\/096120301678646137","article-title":"Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study","volume":"10","author":"Levy","year":"2001","journal-title":"Lupus"},{"key":"10.1016\/j.clp.2020.08.003_bib8","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.ajog.2006.03.087","article-title":"Single versus weekly courses of antenatal corticosteroids: evaluation of safety and efficacy. National Institute of Child Health and human development maternal fetal medicine units network","volume":"195","author":"Wapner","year":"2006","journal-title":"Am J Obstet Gynecol"},{"issue":"Suppl 13","key":"10.1016\/j.clp.2020.08.003_bib9","first-page":"214","article-title":"Hazards of lupus pregnancy","volume":"14","author":"Lockshin","year":"1987","journal-title":"J\u00a0Rheumatol Suppl"},{"issue":"8","key":"10.1016\/j.clp.2020.08.003_bib10","first-page":"1526","article-title":"Clinical predictors of fetal outcome in systemic lupus erythematosus","volume":"25","author":"Rahman","year":"1998","journal-title":"J\u00a0Rheumatol"},{"issue":"7","key":"10.1016\/j.clp.2020.08.003_bib11","first-page":"2244","article-title":"Reduction of extracellular matrix protein expression in human amnion epithelial cells by glucocorticoids: a potential role in preterm rupture of the fetal membranes","volume":"80","author":"Guller","year":"1995","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.clp.2020.08.003_bib12","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1515\/jpme.1996.24.3.243","article-title":"Corticotropin-releasing hormone and related pituitary-adrenal axis hormones in fetal and maternal blood during the second half of pregnancy","volume":"24","author":"Lockwood","year":"1996","journal-title":"J\u00a0Perinat Med"},{"issue":"3","key":"10.1016\/j.clp.2020.08.003_bib13","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3109\/03009742.2011.626442","article-title":"Outcomes after anti-rheumatic drug use before and during pregnancy: a cohort study among 150,000 pregnant women and expectant fathers","volume":"41","author":"Viktil","year":"2012","journal-title":"Scand J Rheumatol"},{"issue":"11","key":"10.1016\/j.clp.2020.08.003_bib14","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.3899\/jrheum.120453","article-title":"Major malformations following exposure to nonsteroidal anti-inflammatory drugs during the first trimester of pregnancy","volume":"39","author":"Daniel","year":"2012","journal-title":"J\u00a0Rheumatol"},{"issue":"9937","key":"10.1016\/j.clp.2020.08.003_bib15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(14)60157-4","article-title":"Preconception low-dose aspirin and pregnancy outcomes: results from the EAGeR randomised trial","volume":"384","author":"Schisterman","year":"2014","journal-title":"Lancet"},{"issue":"9575","key":"10.1016\/j.clp.2020.08.003_bib16","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(07)60712-0","article-title":"Anti-platelet agents for prevention of preeclampsia: a meta-analysis of individual patient data","volume":"369","author":"Askie","year":"2007","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.clp.2020.08.003_bib17","doi-asserted-by":"crossref","first-page":"505.e1-13","DOI":"10.1016\/j.ajog.2014.10.1091","article-title":"Antenatal exposure to indomethacin increases the risk of severe intraventricular hemorrhage, necrotizing enterocolitis, and periventricular leukomalacia: a systematic review with metaanalysis","volume":"212","author":"Hammers","year":"2015","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"10.1016\/j.clp.2020.08.003_bib18","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1345\/aph.1G428","article-title":"Nonsteroidal anti-inflammatory drugs during third trimester and the risk of premature closure of the ductus arteriosus: a meta-analysis","volume":"40","author":"Koren","year":"2006","journal-title":"Ann Pharmacother"},{"issue":"4","key":"10.1016\/j.clp.2020.08.003_bib19","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0002-9378(97)70275-8","article-title":"Is there justification for using indomethacin in preterm labor? An analysis of neonatal risks and benefits","volume":"177","author":"Macones","year":"1997","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.clp.2020.08.003_bib20","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1067\/mob.2001.111718","article-title":"The controversy surrounding indomethacin for tocolysis","volume":"184","author":"Macones","year":"2001","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.clp.2020.08.003_bib21","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/ar1957","article-title":"Anti-inflammatory and immunosuppressive drugs and reproduction","volume":"8","author":"Ostensen","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.clp.2020.08.003_bib22","first-page":"135","article-title":"Nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus. Lupus 2001;10:135\u2013139","volume":"10","author":"Ostensen","year":"2001","journal-title":"Lupus"},{"issue":"4","key":"10.1016\/j.clp.2020.08.003_bib23","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/j.1572-0241.2004.04140.x","article-title":"The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients","volume":"99","author":"Moskovitz","year":"2004","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.clp.2020.08.003_bib24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1053\/gast.2003.50014","article-title":"The Safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study","volume":"124","author":"Francella","year":"2003","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.clp.2020.08.003_bib25","first-page":"19","article-title":"National transplantation pregnancy registry. Update on pregnancy and renal transplantation","volume":"12","author":"Armenti","year":"1998","journal-title":"Nephrol News Issues"},{"issue":"3","key":"10.1016\/j.clp.2020.08.003_bib26","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2165\/00002018-199819030-00005","article-title":"Drug safety issues in pregnancy following transplantation and immunosuppression: effects and outcomes","volume":"19","author":"Armenti","year":"1998","journal-title":"Drug Safety"},{"issue":"7","key":"10.1016\/j.clp.2020.08.003_bib27","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1111\/j.1572-0241.2007.01216.x","article-title":"Therapeutic drug use in women with Crohn's disease and birth outcomes: a Danish nationwide cohort study","volume":"102","author":"Norgard","year":"2007","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"10.1016\/j.clp.2020.08.003_bib28","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/00007890-200104270-00006","article-title":"Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis","volume":"71","author":"Bar Oz","year":"2001","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.clp.2020.08.003_bib29","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1084\/jem.20040165","article-title":"Compromised function of regulatory T\u00a0cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy","volume":"200","author":"Ehrenstein","year":"2004","journal-title":"J\u00a0Exp Med"},{"issue":"9","key":"10.1016\/j.clp.2020.08.003_bib30","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1592\/phco.2005.25.9.1181","article-title":"Infections associated with tumor necrosis factor-alpha antagonists","volume":"25","author":"Rychly","year":"2005","journal-title":"Pharmacotherapy"},{"issue":"4","key":"10.1016\/j.clp.2020.08.003_bib31","first-page":"196","article-title":"Adalimumab: human recombinant immunoglobulin g1 anti-tumor necrosis factor monoclonal antibody","volume":"4","author":"Baker","year":"2004","journal-title":"Rev Gastroenterol Disord"},{"issue":"4","key":"10.1016\/j.clp.2020.08.003_bib32","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.gtc.2009.07.006","article-title":"Pregnancy and inflammatory bowel disease","volume":"38","author":"Mahadevan","year":"2009","journal-title":"Gastroenterol Clin North Am"},{"issue":"3","key":"10.1016\/j.clp.2020.08.003_bib33","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3899\/jrheum.080545","article-title":"A\u00a0safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database","volume":"36","author":"Carter","year":"2009","journal-title":"J\u00a0Rheumatol"},{"issue":"9","key":"10.1016\/j.clp.2020.08.003_bib34","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.3899\/jrheum.101316","article-title":"The distribution of congenital anomalies within the VACTERL association among tumor necrosis factor antagonist-exposed pregnancies is similar to the general population","volume":"38","author":"Crijns","year":"2011","journal-title":"J\u00a0Rheumatol"},{"issue":"9","key":"10.1016\/j.clp.2020.08.003_bib35","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/ajg.2013.171","article-title":"Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease","volume":"108","author":"Gisbert","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clp.2020.08.003_bib36","first-page":"S187","article-title":"Retrospective analysis of certolizumab pegol use during pregnancy: update of impact on birth outcomes","volume":"65","author":"Clowse","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.clp.2020.08.003_bib37","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/acr.22516","article-title":"Proceedings from the American College of Rheumatology Reproductive Health Summit: the management of fertility, pregnancy, and lactation in women with autoimmune and systemic inflammatory diseases","volume":"67","author":"Kavanaugh","year":"2015","journal-title":"Arthritis Care Res\u00a0(Hoboken)"},{"issue":"1","key":"10.1016\/j.clp.2020.08.003_bib38","first-page":"45","article-title":"Teratogenicity of cyclophosphamide in New Zealand white rabbits","volume":"40","author":"Ujhazy","year":"1993","journal-title":"Neoplasma"},{"issue":"3 Pt 2","key":"10.1016\/j.clp.2020.08.003_bib39","first-page":"462","article-title":"Teratogenic effects of first-trimester cyclophosphamide therapy","volume":"72","author":"Kirshon","year":"1988","journal-title":"Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.clp.2020.08.003_bib40","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/(SICI)1096-8628(19990917)86:3<237::AID-AJMG8>3.0.CO;2-V","article-title":"Apparent cyclophosphamide (cytoxan) embryopathy: a distinct phenotype?","volume":"86","author":"Enns","year":"1999","journal-title":"Am J Med Genet"},{"issue":"3","key":"10.1016\/j.clp.2020.08.003_bib41","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1200\/JCO.1999.17.3.855","article-title":"Management of breast cancer during pregnancy using a standardized protocol","volume":"17","author":"Berry","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"issue":"18","key":"10.1016\/j.clp.2020.08.003_bib42","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.1200\/JCO.2005.03.038","article-title":"Chemotherapy for breast cancer during pregnancy: an 18-year experience from five London teaching hospitals","volume":"23","author":"Ring","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"10.1016\/j.clp.2020.08.003_bib43","first-page":"3439","article-title":"Efficacy and Safety of a combined rituximab chemotherapy during pregnancy","volume":"19","author":"Herold","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.clp.2020.08.003_bib44","doi-asserted-by":"crossref","first-page":"e453","DOI":"10.1212\/NXI.0000000000000453","article-title":"Rituximab before and during pregnancy: a systematic review, and a case series in MS and NMOSD","volume":"5","author":"Das","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"10","key":"10.1016\/j.clp.2020.08.003_bib45","first-page":"1426","article-title":"The effects of rituximab treatment during pregnancy on a neonate","volume":"91","author":"Friedrichs","year":"2006","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.clp.2020.08.003_bib46","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1002\/art.1780400527","article-title":"Multiple congenital anomalies associated with weekly low-dose methotrexate treatment of the mother","volume":"40","author":"Buckley","year":"1997","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.clp.2020.08.003_bib47","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/bdra.23003","article-title":"Teratogen update: methotrexate","volume":"94","author":"Hyoun","year":"2012","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"issue":"9","key":"10.1016\/j.clp.2020.08.003_bib48","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1002\/ajmg.a.36625","article-title":"National Birth Defects Prevention Study. Maternal exposure to methotrexate and birth defects: a population-based study","volume":"164A","author":"Dawson","year":"2014","journal-title":"Am J Med Genet A"},{"issue":"12","key":"10.1016\/j.clp.2020.08.003_bib49","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1097\/01.tp.0000252683.74584.29","article-title":"Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus","volume":"82","author":"Sifontis","year":"2006","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.clp.2020.08.003_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ajmg.a.32117","article-title":"In utero exposure to mycophenolate mofetil: a characteristic phenotype?","volume":"146A","author":"Perez-Aytes","year":"2008","journal-title":"Am J Med Genet A"},{"issue":"7","key":"10.1016\/j.clp.2020.08.003_bib51","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1002\/art.34419","article-title":"Pregnancy outcome in women exposed to leflunomide before or during pregnancy","volume":"64","author":"Cassina","year":"2012","journal-title":"Arthritis Rheum"}],"container-title":["Clinics in Perinatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0095510820300993?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0095510820300993?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T15:57:22Z","timestamp":1758815842000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0095510820300993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0095510820300993"],"URL":"https:\/\/doi.org\/10.1016\/j.clp.2020.08.003","relation":{},"ISSN":["0095-5108"],"issn-type":[{"value":"0095-5108","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An Update on Biologic Agents During Pregnancy","name":"articletitle","label":"Article Title"},{"value":"Clinics in Perinatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clp.2020.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}